For PAN patients with early-onset, familial history or poor treatment response, testing for the cat eye syndrome chromosome candidate gene 1 and assessing ADA2 enzyme activity can assist in the diagnosis of DADA2 and facilitate timely treatment with tumor necrosis factor inhibitors. Here, ADA2 is linked to cat-eye syndrome.